SOX2 modulates alternative splicing in transitional cell carcinoma

Biochemical and Biophysical Research Communications

Volumn 393, Issue 3, 2010, Pages 420-425

  Tung, Chun Liang ^a   Hou, Pei Hsuan ^b   Kao, Yung Ling ^b   Huang, Yu Wen ^b   Shen, Chiung Chun ^b   Cheng, Yi Hsin ^b   Wu, Shu Fen ^b   Lee, Moon Sing ^c,d   Li, Chin ^b  

^a CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^b NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

^c TZU CHI UNIVERSITY   (Taiwan)

^d TZU CHI COLLEGE OF TECHNOLOGY   (Taiwan)

Author keywords

Alternative splicing; SOX2; Transitional cell carcinoma

Indexed keywords

E1A PROTEIN; RNA; TRANSCRIPTION FACTOR SOX2;

ALTERNATIVE RNA SPLICING; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA BINDING; TRANSITIONAL CELL CARCINOMA; UPREGULATION;

ADENOVIRUS E1A PROTEINS; ALTERNATIVE SPLICING; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; RNA SPLICE SITES; RNA, MESSENGER; SOXB1 TRANSCRIPTION FACTORS;

EID: 77949261547     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.02.010     Document Type: Article

References (23)

1. Grosso A.R., Martins S., and Carmo-Fonseca M. The emerging role of splicing factors in cancer. EMBO Rep. 9 (2008) 1087-1093
2. Pajares M.J., Ezponda T., Catena R., Calvo A., Pio R., and Montuenga L.M. Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol. 8 (2007) 349-357
3. Karni R., de Stanchina E., Lowe S.W., Sinha R., Mu D., and Krainer A.R. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat. Struct. Mol. Biol. 14 (2007) 185-193
4. Pei D. Regulation of pluripotency and reprogramming by transcription factors. J. Biol. Chem. 284 (2009) 3365-3369
5. Ben-Porath I., Thomson M.W., Carey V.J., Ge R., Bell G.W., Regev A., and Weinberg R.A. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40 (2008) 499-507
6. Stros M., Launholt D., and Grasser K.D. The HMG-box: a versatile protein domain occurring in a wide variety of DNA-binding proteins. Cell. Mol. Life Sci. 64 (2007) 2590-2606
7. Ohe K., Lalli E., and Sassone-Corsi P. A direct role of SRY and SOX proteins in pre-mRNA splicing. Proc. Natl. Acad. Sci. USA 99 (2002) 1146-1151
8. Veretnik S., and Gribskov M. RNA binding domain of HDV antigen is homologous to the HMG box of SRY. Arch. Virol. 144 (1999) 1139-1158
9. Lamm S.H., Engel A., Penn C.A., Chen R., and Feinleib M. Arsenic cancer risk confounder in southwest Taiwan data set. Environ. Health Perspect. 114 (2006) 1077-1082
10. Lai M.C., Kuo H.W., Chang W.C., and Tarn W.Y. A novel splicing regulator shares a nuclear import pathway with SR proteins. EMBO J. 22 (2003) 1359-1369
11. Helfman D.M., Roscigno R.F., Mulligan G.J., Finn L.A., and Weber K.S. Identification of two distinct intron elements involved in alternative splicing of beta-tropomyosin pre-mRNA. Genes Dev. 4 (1990) 98-110
12. Thorsen K., Sorensen K.D., Brems-Eskildsen A.S., Modin C., Gaustadnes M., Hein A.M., Kruhoffer M., Laurberg S., Borre M., Wang K., Brunak S., Krainer A.R., Torring N., Dyrskjot L., Andersen C.L., and Orntoft T.F. Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Mol. Cell. Proteomics 7 (2008) 1214-1224
13. van Weering D.H., Baas P.D., and Bos J.L. A PCR-based method for the analysis of human CD44 splice products. PCR Methods Appl. 3 (1993) 100-106
14. Lee M.S., Huang Y.H., Huang S.P., Lin R.I., Wu S.F., and Li C. Identification of a nuclear localization signal in the polo box domain of Plk1. Biochim. Biophys. Acta 1793 (2009) 1571-1578
15. Yeh M.Y., Yu D.S., Chen S.C., Lin M.S., Chang S.Y., Ma C.P., and Han S.H. Establishment and characterization of a human urinary bladder carcinoma cell line (TSGH-8301). J. Surg. Oncol. 37 (1988) 177-184
16. Tzeng C.C., Liu H.S., Li C., Jin Y.T., Chen R.M., Yang W.H., and Lin J.S. Characterization of two urothelium cancer cell lines derived from a blackfoot disease endemic area in Taiwan. Anticancer Res. 16 (1996) 1797-1804
17. Meisner L.F., Wu S.Q., Christian B.J., and Reznikoff C.A. Cytogenetic instability with balanced chromosome changes in an SV40 transformed human uroepithelial cell line. Cancer Res. 48 (1988) 3215-3220
18. Huang C.S., Shen C.Y., Wang H.W., Wu P.E., and Cheng C.W. Increased expression of SRp40 affecting CD44 splicing is associated with the clinical outcome of lymph node metastasis in human breast cancer. Clin. Chim. Acta 384 (2007) 69-74
19. Watermann D.O., Tang Y., Zur Hausen A., Jager M., Stamm S., and Stickeler E. Splicing factor Tra2-beta1 is specifically induced in breast cancer and regulates alternative splicing of the CD44 gene. Cancer Res. 66 (2006) 4774-4780
20. Cheng C., and Sharp P.A. Regulation of CD44 alternative splicing by SRm160 and its potential role in tumor cell invasion. Mol. Cell. Biol. 26 (2006) 362-370
21. Chapman E.J., Hurst C.D., Pitt E., Chambers P., Aveyard J.S., and Knowles M.A. Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway. Oncogene 25 (2006) 5037-5045
22. Tay Y., Zhang J., Thomson A.M., Lim B., and Rigoutsos I. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 455 (2008) 1124-1128
23. Xu N., Papagiannakopoulos T., Pan G., Thomson J.A., and Kosik K.S. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 137 (2009) 647-658